We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

Contemporary Outcomes of Autologous Stem Cell Transplantation in AL Amyloidosis: Insights from a Decade-Long Multicenter Study

MedXY Editorial Team•Sep 21, 2026•Hematology-Oncology
survival outcomesAL淀粉样变性autologous stem-cell transplantationhematologic response

Highlight

This large retrospective multicenter study of 1047 AL amyloidosis patients undergoing autologous stem cell transplantation (ASCT) from 2010 to 2020 reveals significantly reduced early mortality (3.0% at day 100), high rates of hematologic response post-transplantation (75.4%), and a median overall survival of 6.3 years. Key prognostic factors impacting survival include age, bone marrow plasma cell burden, disease biomarkers, and conditioning regimen intensity. ASCT continues to serve as an effective consolidative strategy in carefully selected patients despite evolving therapeutic landscapes.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Contemporary Surgical Management of Vulvar Cancer: Balancing Improved Survival with Increased Reoperation Rates — Insights from a Finnish Nationwide StudyThis review synthesizes evidence that modern personalized surgical strategies for vulvar squamous cell carcinoma enhance survival outcomes despite higher reoperation rates, emphasizing evolving surgical techniques, sentinel lymph node biopsSep 27, 2026Global Real-World Evidence Shows Survival Benefit of Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple MyelomaMaintenance therapies—lenalidomide, thalidomide, and bortezomib—significantly improve survival after autologous stem cell transplant for multiple myeloma, regardless of initial response status, based on a large global registry analysis.Sep 22, 2026Evaluating First-Line Chemotherapy Strategies in Anaplastic Thyroid Cancer: Insights from a German Multicenter RegistryA multicenter German registry study comparing carboplatin/paclitaxel to other chemotherapy regimens in anaplastic thyroid cancer found no survival advantage, highlighting the importance of molecular diagnostics and multimodal treatment apprSep 21, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Immunotherapy in Head and Neck Squamous Cell Carcinoma with Low PD-L1 Expression: A Meta-Analytic Insight into Survival Outcomes
A meta-analysis reveals immune checkpoint inhibitors may reduce survival in head and neck squamous cell carcinoma patients with PD-L1 combined positive scores less than 1, signaling caution in this subgroup’s treatment.
Sep 21, 2026
Germline Lymphoma-Predisposing Variants: Influence on Age at Diagnosis and Survival Outcomes in Pediatric PatientsThis review synthesizes current evidence on germline lymphoma-predisposing variants, highlighting their impact on earlier cancer onset and variable survival rates in pediatric lymphoma patients, underscoring implications for genetic screeniSep 17, 2026
Comparing CHOP and CHOEP/EPOCH Regimens in Aggressive Adult T-Cell Leukemia/Lymphoma: Insights from an International Cohort StudyThis international cohort study evaluates the effectiveness of CHOEP/EPOCH versus CHOP chemotherapy in aggressive adult T-cell leukemia/lymphoma, revealing subtype-specific survival benefits in lymphomatous ATL but inconclusive results in aSep 17, 2026